Answers · Valuation & Worth
What royalty rate is typical for licensing a patent (by industry)?
Updated June 2026
The short answer
Published royalty-rate surveys commonly cite patent royalties between 0.1 and 8 percent of net sales, with roughly 3 to 6 percent typical across industries. Rates cluster lower in high-volume hardware, where many patents share one product, and higher in software and pharmaceuticals, where a single patent can cover more of the product's value.
Treat every industry benchmark as a starting point for negotiation rather than an answer. Exclusivity, territory, the definition of the royalty base, and how badly the licensee needs the patent routinely move realized rates outside the survey bands.
Commonly cited published royalty ranges by industry group (survey figures, not ipCG data; individual deals routinely fall outside these bands)
| Industry group | Commonly cited range (% of net sales) |
|---|---|
| Software and SaaS | Roughly 5-8%, with wide variance |
| Pharmaceuticals and biotech | Roughly 4-6%; late-stage assets are cited into double digits |
| Medical devices | Roughly 3-5% |
| Consumer products | Roughly 2-5% |
| Electronics and hardware | Roughly 2-4% |
| Chemicals and materials | Roughly 2-4% |
| Automotive and industrial | Roughly 1-3% |
| Semiconductors | Roughly 1-2%, reflecting many patents per product |
Where these numbers come from, and why they spread so wide
The published bands aggregate licensing-executive surveys, disclosed agreements from securities filings, and rates revealed in litigation. That mix is the source of the spread: an exclusive worldwide license with transferred know-how and a bare non-exclusive patent license get averaged into the same industry figure. The base differs too, since a percentage of net sales on a $5 component and on a $50,000 system are different economics at the same headline rate.
So a survey median tells you the neighborhood, never the price. In our licensing engagements the published bands are one input alongside the patent's strength, the products that practice it, and what the licensee's alternatives would cost.
What actually sets the rate
Five levers do most of the work. Exclusivity: exclusive licenses command meaningfully higher rates than non-exclusive ones, because the licensee is buying a market position, not just permission. Necessity: a patent the licensee cannot design around is worth multiples of one they can engineer past in a quarter. The base: a high rate on a narrowly defined base can pay less than a modest rate on a broad one, which is why base definitions get negotiated harder than rates. Patent strength: claims that have survived challenge, or that read cleanly on shipping products, carry premiums. And risk allocation: rates fall when the licensor takes milestone or minimum-royalty risk off the table.
The negotiation is ultimately about splitting the licensee's benefit. Estimate what practicing the patent earns them or saves them, and the defensible rate range falls out of that math far more reliably than out of any survey table.
Rules of thumb worth retiring
The 25 percent rule, which handed a quarter of product profit to the patent holder, was rejected by US courts as damages evidence in 2011 and should not anchor a negotiation. Claims that an industry has one standard rate are equally suspect; the published data shows wide dispersion inside every industry. And a rate quoted without its base, its exclusivity terms, and its duration is not a rate, it is a slogan.
Related questions
Should the royalty be on gross sales, net sales, or profit?
Net sales is the most common base in published agreements, with deductions defined in the contract. Profit-based royalties are rarer because profit is easier to manipulate and harder to audit. Whatever the base, define it precisely; more disputes start there than at the rate.
Is a lump sum better than a running royalty?
A lump sum trades upside for certainty: you are paid even if the product flops, and capped if it takes off. Running royalties track actual use but require audit rights and a counterparty you trust to report. Many deals blend the two with an upfront payment plus a running rate.
Is a negotiated royalty the same as a reasonable royalty in litigation?
No. A reasonable royalty in litigation is a legal damages construct determined by courts with testifying experts, under standards your counsel can explain. Negotiated rates inform it but the two are set by different processes.
How does ipCG support a licensing negotiation?
We build the economic case: patent strength, evidence of use, the licensee's benefit, and a supported rate range. Our ipValue Model has supported over $2 billion in cumulative transaction value. Your attorney negotiates terms and papers the agreement; we are a consultancy, not a law firm.
Price the license before you sit down
Bring us the patent and the prospective licensee. We will tell you what the economics support before anyone anchors the negotiation. Discovery calls are free.
Talk with Our TeamRelated
ipCapital Group is a consultancy, not a law firm, and nothing on this page is legal advice. Dollar figures on this page are typical market ranges for professional IP services, drawn from published sources and industry experience across a variety of providers. They are not an ipCG quote or rate card; every ipCG engagement is individually scoped and priced. See how our pricing works.